Adc Therapeutics Ltd (ADCT) 2024 Q4 法說會逐字稿

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Operator

    Operator

  • Good morning, ladies and gentlemen, and welcome to the ATC Therapeutics -- ADC Therapeutics fourth-quarter fiscal year 2024 earnings conference call. (Operator Instructions)

    各位女士、先生,早安,歡迎參加 ATC Therapeutics -- ADC Therapeutics 2024 會計年度第四季財報電話會議。(接線員指示)

  • I will now turn the call over to Marcy Graham, Investor Relations Officer for ADC Therapeutics. Marcy, please go ahead.

    現在我將把電話交給 ADC Therapeutics 投資人關係主管 Marcy Graham。Marcy,請開始。

  • Marcy Graham - Investor Relations

    Marcy Graham - Investor Relations

  • Thank you, operator. This morning, we issued a press release announcing our fourth quarter and full year 2024 financial results and business update. The release and the slides we will use in today's presentation are available on the Investors section of the ADC Therapeutics website.

    謝謝,接線員。今天早上,我們發布新聞稿,公布 2024 年第四季及全年財務結果與業務更新。該新聞稿以及我們在今日簡報中將使用的投影片,可於 ADC Therapeutics 官網的「投資人」專區取得。

  • I'm joined on today's call by our Chief Executive Officer, Ameet Mallik, who will discuss our operational performance and recent business highlights; followed by our Chief Financial Officer, Pepe Carmona, who will review our fourth quarter and full year 2024 financial results. We will then open the call to questions.

    今天與我一同參與電話會議的有本公司執行長 Ameet Mallik,他將說明我們的營運表現與近期業務重點;接著由財務長 Pepe Carmona 回顧 2024 年第四季及全年財務結果。之後我們將開放提問。

  • Before we begin, I would like to remind listeners that some of the statements made during this conference call will contain forward-looking statements within the meaning of the safe harbor provisions of the US Private Securities Litigation Reform Act of 1995.

    在開始之前,我想提醒各位聽眾,本次電話會議中的部分陳述將構成前瞻性陳述,符合 1995 年《美國私人證券訴訟改革法》安全港條款之定義。

  • These forward-looking statements are subject to certain known and unknown risks and uncertainties, and actual results, performance and achievements could differ materially. They are identified and described in the accompanying slide presentation and in the company's filings with the SEC, including Form 10-K, 10-Q and 8-K.

    這些前瞻性陳述受到若干已知與未知風險及不確定性影響,實際結果、表現與成就可能出現重大差異。相關風險已在隨附的投影片簡報以及公司向美國證券交易委員會(SEC)提交的文件中加以辨識與說明,包括 10-K、10-Q 與 8-K 表格。

  • ADC Therapeutics is providing this information as of today's date and does not undertake any obligation to update any forward-looking statements contained in this conference call as a result of new information, future events or circumstances, except as required by law.

    ADC Therapeutics 係以今日日期提供本資訊,除法律另有規定外,對於因新資訊、未來事件或情勢所致而需更新本次電話會議中任何前瞻性陳述,公司不承擔任何義務。

  • The company cautions investors not to place undue reliance on these forward-looking statements. Today's presentation also includes non-GAAP financial reporting. These non-GAAP measures should be considered in addition to and not in isolation or as a substitute for the information prepared in accordance with GAAP.

    公司提醒投資人勿過度依賴這些前瞻性陳述。今日簡報亦包含非 GAAP 財務報告。這些非 GAAP 指標應與依 GAAP 編製之資訊一併考量,不應單獨使用,亦不應作為 GAAP 資訊之替代。

  • You should refer to the company's fourth quarter earnings release for information and reconciliations of historical non-GAAP measures to the comparable GAAP financial measures. I will now turn the call over to our CEO, Ameet Mallik. Ameet?

    有關歷史非 GAAP 指標與可比較之 GAAP 財務指標之資訊與調節表,請參閱公司第四季財報新聞稿。現在我將把電話交給我們的執行長 Ameet Mallik。Ameet?

  • Ameet Mallik - Chief Executive Officer, Director

    Ameet Mallik - Chief Executive Officer, Director

  • Thanks, Marcy, and good morning, everyone. Thank you for joining us on today's call. Looking back, 2024 was a year focused on execution, where we achieved multiple exciting milestones helping to advance our strategy to unlock value for our shareholders.

    謝謝你,Marcy,各位早安。感謝各位參加今天的電話會議。回顧 2024 年,這是一個專注於執行的一年;我們達成多項令人振奮的里程碑,推進我們為股東釋放價值的策略。

  • We made significant progress across key areas in our ADC portfolio, both with ZYNLONTA and our early-stage solid tumor pipeline, all while strengthening our balance sheet. We are confident in the path ahead as we work to make an impact for more patients moving forward.

    我們在 ADC 產品組合的關鍵領域取得重大進展,包括 ZYNLONTA 以及早期實體腫瘤研發管線,同時也強化了資產負債表。展望未來,我們對前方道路充滿信心,並將持續努力為更多病患帶來影響。

  • Among our key 2024 accomplishments, we reached commercial brand profitability with ZYNLONTA as we continue to maintain our position in the highly competitive third line plus DLBCL space. Sales of $69.3 million were in line with the prior year despite the growth of bispecifics in the setting.

    在 2024 年的主要成果中,隨著我們持續在競爭激烈的三線以上 DLBCL 市場維持地位,ZYNLONTA 已達到商業品牌獲利。銷售額為 6,930 萬美元,儘管該治療情境中雙特異性抗體的使用成長,仍與前一年持平。

  • We made significant progress in advancing our strategy to expand the use of ZYNLONTA into earlier lines of DLBCL and indolent lymphomas. December included completion of enrollment in our pivotal Phase 3 LOTIS-5 trial, and an initial efficacy and safety update on part 2 of our Phase 1b LOTIS-7 trial. In addition, we were pleased to see Phase 2 IIT indolent lymphoma data presented at ASH and the simultaneous publication of the follicular lymphoma data in Lancet Haematology.

    我們在推進策略方面取得重大進展,致力將 ZYNLONTA 的使用擴展至 DLBCL 的更早治療線別以及惰性淋巴瘤。12 月我們完成關鍵性第三期 LOTIS-5 試驗的收案,並就第一期 b LOTIS-7 試驗第 2 部分提供初步療效與安全性更新。此外,我們也很高興看到惰性淋巴瘤第二期研究者發起試驗(IIT)數據於 ASH 發表,並同步在《Lancet Haematology》發表濾泡性淋巴瘤數據。

  • From a solid tumor perspective, we continue to advance our exatecan based preclinical candidates. The most advanced targets are PSMA and Claudin-6, and we continue to seek potential research collaborations to further advance our programs.

    在實體腫瘤方面,我們持續推進以 exatecan 為基礎的臨床前候選藥物。目前最先進的標的為 PSMA 與 Claudin-6,我們也持續尋求潛在研究合作,以進一步推動相關計畫。

  • Additionally, in a year marked by continued progression, we were able to achieve a double digit reduction in operating expenses for our second year in a row. In addition, we strengthened our balance sheet through an equity financing, providing an expected cash runway into the second half of 2026. We are proud of what we accomplished in 2024 and are confident in our path forward.

    此外,在持續推進的一年中,我們連續第二年達成營運費用的兩位數百分比下降。同時,我們透過股權融資強化資產負債表,預期現金可支應至 2026 年下半年。我們為 2024 年的成果感到自豪,並對未來的發展路徑充滿信心。

  • In support of our commitment to further expand usage of ZYNLONTA, we are pursuing the substantially larger opportunity in earlier lines of DLBCL therapy with combinations through LOTIS-5 and LOTIS-7. With LOTIS-5, we are pleased to have closed 2024 by completing enrollment of our Phase 3 trial, bringing us a step closer to providing a potential combination treatment in the second-line plus DLBCL setting.

    為支持我們進一步擴大 ZYNLONTA 使用的承諾,我們正透過 LOTIS-5 與 LOTIS-7 的合併療法,追求在 DLBCL 更早治療線別中規模大幅更大的機會。就 LOTIS-5 而言,我們很高興在 2024 年底完成第三期試驗收案,使我們更接近於二線以上 DLBCL 治療情境中提供潛在的合併治療方案。

  • Initial data from the safety lead-in portion of the study showed an overall response rate of 80% and a complete response rate of 50% with no new safety signals, demonstrating that this combination of ZYNLONTA plus rituximab has the potential to provide competitive second-line plus efficacy with a favorable safety profile, allowing broad accessibility.

    研究安全性導入(safety lead-in)部分的初步數據顯示,總反應率為 80%,完全反應率為 50%,且未出現新的安全性訊號,顯示 ZYNLONTA 與利妥昔單抗(rituximab)之合併療法有潛力在二線以上提供具競爭力的療效,並具良好安全性特徵,因而可廣泛可及。

  • Updated data are expected by the end of 2025 once the prespecified number of events is reached. With LOTIS-7, in December, we reported encouraging initial data, including safety and efficacy in a subset of patients from the part 2 dose expansion of the ZYNLONTA plus glofitamab combination arm in non-Hodgkin lymphoma.

    一旦達到預先規定的事件數,預期將於 2025 年底提供更新數據。就 LOTIS-7 而言,我們於 12 月公布令人鼓舞的初步數據,包括在非霍奇金淋巴瘤中,ZYNLONTA 與 glofitamab 合併治療組於第 2 部分劑量擴增中一部分病患的安全性與療效。

  • Initial data showed a best overall response rate among the 18 efficacy evaluable relapsed or refractory DLBCL patients of 94% and a complete response rate of 72%. These encouraging efficacy data were observed across patients with different numbers of lines and types of prior treatments.

    初步數據顯示,在 18 名可評估療效的復發或難治性 DLBCL 病患中,最佳總反應率為 94%,完全反應率為 72%。這些令人鼓舞的療效數據在先前治療線數與治療類型不同的病患中皆有觀察到。

  • Initial safety data on all 29 NHL patients suggest the combination is generally well tolerated with no dose limiting toxicities across all dose levels. We believe these initial data support our hypothesis that combining these two potent approved single agent drugs with complementary mechanisms of action will yield additive or synergistic efficacy, a manageable safety profile and accessibility across care settings. This combination has the potential to be best-in-class in a highly competitive market.

    針對所有 29 名 NHL 病患的初步安全性數據顯示,該合併療法整體耐受性良好,在所有劑量水準下均未出現劑量限制性毒性。我們認為,這些初步數據支持我們的假設:將兩種已核准且具強效、作用機轉互補的單藥合併使用,可帶來相加或協同的療效、可管理的安全性特徵,以及在不同照護場域的可及性。在競爭激烈的市場中,該合併療法有潛力成為同類最佳(best-in-class)。

  • Enrollment of 40 patients in dose expansion is expected to be completed in the second quarter of 2025. We expect to share data on a subset of patients in the second quarter of this year, with a full or more mature data update anticipated during the second half of 2025.

    預期將於 2025 年第二季完成劑量擴增階段 40 名病患的收案。我們預期於今年第二季分享部分病患的數據,並預計在 2025 年下半年提供完整或更成熟的數據更新。

  • In addition to our expansion trials in DLBCL, promising Phase 2 data from two key investigator-initiated trials led by the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine were reported in indolent lymphomas with presentations at ASH on ZYNLONTA in combination with rituximab in high-risk relapsed or refractory follicular lymphoma and as monotherapy in relapsed or refractory marginal zone lymphoma with a simultaneous Lancet Haematology publication of the FL data.

    除了我們在 DLBCL 的擴展試驗外,由邁阿密大學米勒醫學院 Sylvester 綜合癌症中心主導的兩項關鍵研究者發起試驗(IIT)所取得的具前景第二期數據,也已在惰性淋巴瘤領域公布;其中包括在 ASH 會議上發表 ZYNLONTA 與利妥昔單抗(rituximab)聯合用於高風險復發或難治性濾泡性淋巴瘤(FL)的數據,以及 ZYNLONTA 單藥用於復發或難治性邊緣區淋巴瘤(MZL)的數據;同時,FL 數據亦於《Lancet Haematology》同步發表。

  • Data showed strong results in high-risk relapse/refractory FL patients treated with the combination of ZYNLONTA plus rituximab with the best overall response rate of 97% and a complete response rate of 77%. In addition, ZYNLONTA data from the relapsed or refractory MZL study showed clinically meaningful activity with an overall response rate of 91% and a complete response rate of 70%.

    數據顯示,對於接受 ZYNLONTA 加利妥昔單抗聯合治療的高風險復發/難治性 FL 患者,結果強勁,最佳總反應率達 97%,完全反應率達 77%。此外,復發或難治性 MZL 研究中的 ZYNLONTA 數據顯示具臨床意義的活性,總反應率為 91%,完全反應率為 70%。

  • We look forward to further updates at future medical conferences from these two studies evaluating the potential of ZYNLONTA in FL and MZL. With sufficient data, we plan to discuss the path forward with regulatory authorities as well as seek inclusion in compendia. Looking forward into 2025, we expect to have multiple data catalysts, which can further derisk ZYNLONTA life cycle management opportunities.

    我們期待未來在醫學會議上,這兩項評估 ZYNLONTA 於 FL 與 MZL 潛力的研究能帶來更多更新。在取得足夠數據後,我們計畫與監管機關討論後續推進路徑,並尋求納入臨床用藥彙編(compendia)。展望 2025 年,我們預期將有多項數據催化劑,可進一步降低 ZYNLONTA 生命週期管理機會的風險。

  • Together, these have the potential to lead to a peak revenue of $600 million to $1 billion in the US, assuming regulatory approval and compendia listing. Within our current indication, our commercial strategy remains focused on relapsed or refractory DLBCL patients, who need a treatment with a fast, durable response and a manageable safety profile, which can be administered in the outpatient setting.

    綜合而言,在假設獲得監管核准並列入臨床用藥彙編的前提下,這些機會有望在美國帶來 6 億至 10 億美元的峰值營收。在我們目前的適應症中,我們的商業策略仍聚焦於復發或難治性 DLBCL 患者;他們需要一種反應快速且持久、並具可管理安全性特徵、且可於門診環境給藥的治療。

  • We are holding our own in the competitive third-line plus market, demonstrating that ZYNLONTA has a place of a monotherapy with a significantly greater opportunity as we move toward combinations in earlier lines of DLBCL therapy.

    在競爭激烈的第三線及以上市場中,我們仍能站穩腳步,證明 ZYNLONTA 作為單藥治療具一席之地;且隨著我們朝 DLBCL 較早治療線別的聯合療法推進,機會將顯著擴大。

  • We believe LOTIS-5 has the potential to take ZYNLONTA to $200 million to $300 million in peak sales as we expand into the second-line setting, taking the company to profitability. This is driven by doubling the patient population, extending the duration of therapy and improving the clinical profile versus our current indication as a monotherapy.

    我們相信 LOTIS-5 有潛力在我們擴展至第二線治療情境時,將 ZYNLONTA 的峰值銷售推升至 2 億至 3 億美元,並使公司達到獲利。其驅動因素包括患者族群倍增、治療期間延長,以及相較於我們目前單藥適應症更佳的臨床特徵。

  • Market research suggests that only about 50% of the second line population are expected to have access to and/or be suitable for CAR-T and bispecific based therapies. For patients who are not treated with or progress on a CAR-T or bispecific, ZYNLONTA plus rituximab has the potential to have a differentiated clinical profile with high and durable response rates, a manageable safety profile and ease of administration.

    市場研究顯示,預期第二線患者族群中僅約 50% 能夠取得 CAR-T 與/或適合接受雙特異性抗體(bispecific)治療。對於未接受 CAR-T 或雙特異性治療,或在其後疾病進展的患者,ZYNLONTA 加利妥昔單抗有潛力展現差異化的臨床特徵,包括高且持久的反應率、可管理的安全性特徵,以及給藥便利性。

  • With LOTIS-7, we estimate we can expand the total opportunity for ZYNLONTA in DLBCL to $500 million to $800 million in peak revenue with regulatory approval and compendia listing. If the data persists, we believe ZYNLONTA plus glofitamab has the potential to transform the future lymphoma treatment paradigm by becoming the preferred bispecific combination in the second-line plus DLBCL setting.

    透過 LOTIS-7,我們估計在獲得監管核准並列入臨床用藥彙編的前提下,可將 ZYNLONTA 在 DLBCL 的總機會擴大至 5 億至 8 億美元的峰值營收。若數據得以持續,我們相信 ZYNLONTA 加 glofitamab 有潛力改變未來淋巴瘤治療典範,成為第二線及以上 DLBCL 情境中首選的雙特異性聯合療法。

  • Additionally, in indolent lymphomas, there is a clear unmet need in both relapsed or refractory marginal zone lymphoma and relapsed or refractory follicular lymphoma. We are encouraged by the data seen in the Phase 2 IIT suggesting a ZYNLONTA regimen could provide significant benefit in these indolent lymphomas and plan to engage regulatory agencies and pursue competitive strategies as soon as sufficient data are available.

    此外,在惰性淋巴瘤方面,無論是復發或難治性邊緣區淋巴瘤,或復發或難治性濾泡性淋巴瘤,皆存在明確未被滿足的醫療需求。我們對第二期 IIT 所見數據感到鼓舞,該數據顯示 ZYNLONTA 治療方案可在這些惰性淋巴瘤中提供顯著效益;一旦取得足夠數據,我們計畫與監管機構接洽並推進具競爭力的策略。

  • The indolent lymphomas opportunity could provide additional peak revenue of $100 million to $200 million. Taken together, we believe we are well positioned for success as we progress toward key milestones in 2025 and beyond. With that, I would like to turn the call over to Pepe.

    惰性淋巴瘤的機會可額外帶來 1 億至 2 億美元的峰值營收。綜合而言,我們相信隨著我們邁向 2025 年及其後的關鍵里程碑,我們已具備良好成功定位。接下來,我想把電話會議交給 Pepe。

  • Jose Carmona - Chief Financial Officer

    Jose Carmona - Chief Financial Officer

  • Thank you. As Ameet has noted, we achieved many milestones in 2024, including reducing operating expenses and strengthening the balance sheet. On the financial front, we remain well capitalized, ending the year with $251 million in cash and cash equivalents, which is expected to fund operations into the second half of 2026 based on our current plans.

    謝謝。如 Ameet 所提到的,我們在 2024 年達成多項里程碑,包括降低營運費用並強化資產負債表。在財務方面,我們仍具充足資本,年底現金及約當現金為 2.51 億美元;依據我們目前計畫,預期可支應營運至 2026 年下半年。

  • ZYNLONTA net product revenues in fourth quarter 2024 were $16.4 million as compared to $16.6 million in the same quarter of 2023. For the full year 2024, net product revenues were $69.3 million as compared to $69.1 million in 2023.

    ZYNLONTA 於 2024 年第四季的產品淨營收為 1,640 萬美元,相較於 2023 年同季的 1,660 萬美元。2024 年全年產品淨營收為 6,930 萬美元,相較於 2023 年的 6,910 萬美元。

  • Throughout 2024, we maintained our disciplined capital allocation strategy and decreased operating expenses by 13% year-over-year on a non-GAAP basis, which excludes stock-based compensation. In the fourth quarter, our non-GAAP operating expenses decreased versus prior year by 15% due to efficiencies in our operations and diligent portfolio management decisions.

    在 2024 年全年,我們維持嚴謹的資本配置策略,並在非 GAAP 基礎上將營運費用年減 13%(非 GAAP 不包含以股份為基礎之酬勞)。在第四季,由於營運效率提升以及審慎的產品組合管理決策,我們的非 GAAP 營運費用較前一年下降 15%。

  • You can find the reconciliation of GAAP measures to non-GAAP measures in the accompanying financial tables of the press release issued earlier today and in the appendix of this presentation. On a GAAP basis, we reported a net loss of $30.7 million for the quarter or $0.29 per basic and diluted share as compared to net loss of $85 million or a net loss of $1.03 per basic and diluted share for the same period in 2023.

    您可在今日稍早發布之新聞稿所附財務表格,以及本簡報附錄中,找到 GAAP 指標與非 GAAP 指標之調節表。以 GAAP 基礎計算,我們本季淨損為 3,070 萬美元,或每股基本及稀釋淨損 0.29 美元;相較之下,2023 年同期淨損為 8,500 萬美元,或每股基本及稀釋淨損 1.03 美元。

  • Net loss for the full year ended December 31, 2024, was $157.8 million or a net loss of $1.62 per basic and diluted share as compared to a net loss of $240.1 million or a net loss of $2.94 per basic and diluted share for the full year ended December 31, 2023.

    截至 2024 年 12 月 31 日止全年淨損為 1.578 億美元,或每股基本及稀釋淨損 1.62 美元;相較之下,截至 2023 年 12 月 31 日止全年淨損為 2.401 億美元,或每股基本及稀釋淨損 2.94 美元。

  • The decrease in net loss during both periods is primarily attributable to lower income tax expenses and lower operating expenses. On a non-GAAP basis, adjusted net loss was $26.5 million or an adjusted net loss of $0.25 per basic and diluted share as compared to adjusted net loss of $79.5 million or $0.97 per basic and diluted share for the same period in 2023.

    兩個期間淨損下降主要歸因於所得稅費用較低以及營運費用較低。以非 GAAP 基礎計算,調整後淨損為 2,650 萬美元,或每股基本及稀釋調整後淨損 0.25 美元;相較之下,2023 年同期調整後淨損為 7,950 萬美元,或每股基本及稀釋 0.97 美元。

  • Adjusted net loss for the full year ended December 31, 2024, was $111.4 million or an adjusted net loss of $1.15 per basic and diluted share as compared to net loss of $185.7 million or an adjusted net loss of $2.27 per basic and diluted share for the full year ended December 31, 2023.

    截至 2024 年 12 月 31 日止全年調整後淨損為 1.114 億美元,或每股基本及稀釋調整後淨損 1.15 美元;相較之下,截至 2023 年 12 月 31 日止全年為 1.857 億美元,或每股基本及稀釋調整後淨損 2.27 美元。

  • The decrease in net loss and adjusted net loss during both periods is primarily attributable to lower income tax expenses and lower operating expenses. With our current balance sheet, we believe we are well financed to continue to pursue our corporate strategy.

    兩個期間淨虧損及經調整淨虧損的下降,主要歸因於所得稅費用較低以及營運費用較低。以我們目前的資產負債表而言,我們認為資金充裕,足以持續推進公司的企業策略。

  • As a reminder, hematology continues to be the primary focus of our capital allocation. And within this, our key objective is to create value by expanding the use of ZYNLONTA beyond our current indication. We expect to achieve this by fully supporting our commercialization efforts in the US directly and through our partnership outside the US.

    提醒一下,血液腫瘤學仍是我們資本配置的主要重點。在此之中,我們的關鍵目標是透過將 ZYNLONTA 的使用擴展至目前適應症以外來創造價值。我們預期將透過在美國直接、以及在美國以外透過合作夥伴,全力支持商業化推進工作來達成此目標。

  • In addition, we continue to pursue research collaborations to advance our early-stage solid tumor pipeline. With that, I will turn the call back over to Ameet.

    此外,我們也持續推動研究合作,以推進我們早期實體腫瘤產品線。接下來,我把電話交回給 Ameet。

  • Ameet Mallik - Chief Executive Officer, Director

    Ameet Mallik - Chief Executive Officer, Director

  • Thanks, Pepe. With a year of completed milestones behind us, we enter 2025 with great confidence, proud of what we have achieved and excited for what is to come. Within our current ZYNLONTA indication, we maintained our annual revenue in line with prior year.

    謝謝你,Pepe。在完成一年的里程碑之後,我們帶著高度信心邁入 2025 年,為已達成的成果感到自豪,也對未來充滿期待。在 ZYNLONTA 目前的適應症範圍內,我們的年度營收維持與前一年大致一致。

  • We believe the real growth opportunity comes with the expansion of ZYNLONTA, both through regulatory approvals as well as inclusion in guidelines, and we are confident in the multiple pathways we have to get there. We continue to be encouraged by ZYNLONTA's consistently strong clinical profile, both as monotherapy and in combinations, giving us confidence in the ultimate success of our expansion strategy.

    我們相信,真正的成長機會來自 ZYNLONTA 的擴展,包含透過監管核准以及納入治療指引;我們也對達成此目標的多條途徑充滿信心。ZYNLONTA 無論作為單藥或合併療法,皆展現一貫強勁的臨床特性,這讓我們對擴展策略最終成功更具信心。

  • 2025 will be a period of important data readouts as we progress towards the key milestones shared today, potentially derisking and setting us up to grow our ZYNLONTA brand significantly in the future. As we build on the strength of our established commercial foundation of ZYNLONTA with the expected expansion into the second line plus DLBCL and indolent lymphomas, we believe we have the potential to reach $600 million to $1 billion in peak revenue in the US on our journey to bring these important treatments to patients who need them.

    2025 年將是重要數據讀出的一年,隨著我們朝向今天分享的關鍵里程碑推進,這些數據可能有助於降低風險,並為我們未來顯著擴大 ZYNLONTA 品牌成長奠定基礎。在我們既有的 ZYNLONTA 商業化基礎上,隨著預期擴展至二線以上 DLBCL 及惰性淋巴瘤,我們相信在美國的峰值營收有潛力達到 6 億至 10 億美元,並在將這些重要治療帶給有需要的病患的過程中實現此目標。

  • Beyond this, we believe there is additional value creation opportunity with our pre-clinical solid tumors portfolio as we pursue potential research collaborations. Looking ahead, I am confident that ADC Therapeutics is well positioned to make a truly meaningful impact for patients while driving value creation for all our stakeholders.

    除此之外,隨著我們尋求潛在研究合作,我們相信臨床前實體腫瘤產品組合亦存在額外的價值創造機會。展望未來,我有信心 ADC Therapeutics 已具備良好定位,能為病患帶來真正有意義的影響,同時為所有利害關係人創造價值。

  • We can now open the line for questions. Operator?

    我們現在可以開放提問。接線員?

  • Operator

    Operator

  • (Operator Instructions) Eric Schmidt, Cantor.

    (接線員指示) Eric Schmidt,Cantor。

  • Eric Schmidt - Analyst

    Eric Schmidt - Analyst

  • Good morning. Thanks for taking my question. Maybe just a first real quick one on the LOTIS-7 update in Q2. Is there going to be a specific forum that you have in mind or timing within the quarter we can look to?

    早安。謝謝讓我提問。先快速問第一個,關於第二季 LOTIS-7 的更新。你們是否已有特定的發表場合或是我們可以期待在該季度內的哪個時間點?

  • Ameet Mallik - Chief Executive Officer, Director

    Ameet Mallik - Chief Executive Officer, Director

  • Good question. We haven't disclosed yet what form or exact timing within Q2 that we're going to be sharing the data. But what I can tell you is that we're on track to enroll the 40 patients in the dose expansion in the second quarter. We'll share a portion of those patients -- safety and efficacy data on a portion of those patients in the second quarter and then data on all 40 of those patients in the second half of the year.

    好問題。我們尚未揭露將以何種形式或在第二季的確切時間點分享數據。但我可以告訴你的是,我們正按計畫在第二季完成劑量擴增隊列 40 位病患的入組。我們會在第二季分享其中一部分病患的數據——也就是部分病患的安全性與療效數據;並在下半年分享全部 40 位病患的數據。

  • Eric Schmidt - Analyst

    Eric Schmidt - Analyst

  • Thanks for that, repetitive response. And then second question, just with regard to your newest competitor, latest competitor, I guess, in what's already a fairly crowded marketplace, the existing market for ZYNLONTA and relapsed/refractory NHL, obviously, we saw the Pfizer approval of ADCETRIS. Is it too early to say whether you've got a real challenge there? I know you've guided to kind of flattish revenue for the year. Thank you.

    謝謝,你的回答有點重複。第二個問題,關於你們最新的競爭對手——我想在一個本來就相當擁擠的市場中——也就是 ZYNLONTA 與復發/難治性 NHL 的既有市場;顯然我們看到輝瑞的 ADCETRIS 獲得核准。現在判斷你們是否面臨真正的挑戰,是否還太早?我知道你們對今年的指引大致是營收持平。謝謝。

  • Ameet Mallik - Chief Executive Officer, Director

    Ameet Mallik - Chief Executive Officer, Director

  • Yeah, I know, as you said, the triplet of ADCETRIS plus R-squared was recently approved in the third-line setting based on the ECHELON-3 study. We believe this is going to have limited impact as physicians have access, as you said, to multiple options.

    是的,正如你所說,ADCETRIS 加上 R-squared 的三聯療法,近期基於 ECHELON-3 研究在三線治療情境獲得核准。我們認為其影響將有限,因為臨床醫師如你所說,已有多種選擇可用。

  • And we believe based on a lot of the quantitative market research we've done that any use is likely going to be in place of older regimens such as R-squared or R-based chemo in the third-line plus DLBCL setting.

    而且根據我們所做的大量量化市場研究,我們認為其使用很可能會取代較舊的療法方案,例如 R-squared 或以 R 為基礎的化療,用於三線以上 DLBCL 的治療情境。

  • Eric Schmidt - Analyst

    Eric Schmidt - Analyst

  • Thanks a lot.

    非常感謝。

  • Ameet Mallik - Chief Executive Officer, Director

    Ameet Mallik - Chief Executive Officer, Director

  • Yeah, thank you.

    好的,謝謝。

  • Operator

    Operator

  • Kelly Shi, Jefferies.

    Kelly Shi,Jefferies。

  • Kelly Shi - Analyst

    Kelly Shi - Analyst

  • Thank you for taking my questions. For LOTIS-7, do we expect a meeting with the regulatory agencies after second half update? And if that's the case, would we hear from ADC? And if this info could actually share to the public domain? And secondly, what is your estimate of ZYNLONTA's market opportunity in indolent lymphoma, including follicular lymphoma and marginal zone lymphoma? Thank you.

    謝謝讓我提問。關於 LOTIS-7,我們是否預期在下半年更新後與監管機構開會?如果是的話,我們會從 ADC 那邊聽到相關訊息嗎?而且這些資訊是否可以對外公開?第二個問題,你們如何估計 ZYNLONTA 在惰性淋巴瘤(包含濾泡性淋巴瘤與邊緣區淋巴瘤)的市場機會?謝謝。

  • Ameet Mallik - Chief Executive Officer, Director

    Ameet Mallik - Chief Executive Officer, Director

  • Okay, so yeah, once sufficient data is available on the 40 patients and we have the correct follow-up, we do plan to pursue discussions from regulatory authorities likely in the second half of this year. We also plan to pursue compendia strategy.

    好的,是的,一旦 40 位病患有足夠數據且完成適當的追蹤,我們確實計畫在今年下半年與監管機關展開討論。我們也計畫推進藥典(compendia)策略。

  • We know that based on some of the recent inclusions of bispecific combinations and NCCN guidelines, we believe that the publication of data on approximately 100 patients at the selected dose would be sufficient for submission to compendia. So we do plan to pursue both a regulatory strategy and a compendia strategy for LOTIS-7.

    我們知道,基於近期雙特異性抗體合併療法的納入以及 NCCN 指引的情況,我們相信在選定劑量下約 100 位病患的數據發表,將足以用於向藥典提交。因此,我們確實計畫同時推進 LOTIS-7 的監管策略與藥典策略。

  • With regards to the indolent lymphoma opportunity, as you know, we presented, we think, quite compelling data, both in marginal zone lymphoma and follicular lymphoma at ASH this past year and those studies continue.

    至於惰性淋巴瘤的機會,如你所知,我們在去年 ASH 上於邊緣區淋巴瘤與濾泡性淋巴瘤都發表了我們認為相當具說服力的數據,而這些研究仍在持續進行。

  • Based on the opportunity, the potential regulatory approval and certainly compendia from those studies, we believe that the peak opportunity for indolent lymphomas will be somewhere in the $100 million to $200 million range.

    基於這些研究所帶來的機會、潛在的監管核准,以及當然也包括藥典收錄的可能性,我們相信惰性淋巴瘤的峰值機會將落在 1 億至 2 億美元之間。

  • Kelly Shi - Analyst

    Kelly Shi - Analyst

  • Thank you.

    謝謝。

  • Operator

    Operator

  • Michael Schmidt, Guggenheim.

    Michael Schmidt,Guggenheim。

  • Michael Schmidt - Analyst

    Michael Schmidt - Analyst

  • Hey guys, thanks for taking my questions. By the end of the year, you should most likely also have the results of the LOTIS-5 trial in hands. And I guess I'm just wondering how does your LOTIS-7 strategy -- I mean how is it impacted by potential outcomes of LOTIS-5 by the end of the year? And then I had a follow-up.

    各位好,謝謝讓我提問。到今年年底,你們很可能也會拿到 LOTIS-5 試驗的結果。我想問的是,你們的 LOTIS-7 策略——也就是說——在年底 LOTIS-5 可能出現的結果之下,會受到什麼影響?接著我還有一個追問。

  • Ameet Mallik - Chief Executive Officer, Director

    Ameet Mallik - Chief Executive Officer, Director

  • Okay. Well, it's a great question. We know that in this market, outside of the front line, really no given treatment sort of dominates. A lot of the physicians really make treatment choices based on efficacy, safety and accessibility profile, but in the context of individual patient needs. So for example, you see something like a CAR-T, which has outstanding efficacy, only capture about 20% of the share.

    好的。嗯,這是個很好的問題。我們知道在這個市場中,除了一線治療之外,實際上沒有任何既定治療真正占據主導地位。許多醫師在做治療選擇時,主要會依據療效、安全性與可近性(可取得性)的特徵,但會放在個別病患需求的脈絡下考量。例如,你會看到像 CAR-T 這樣療效非常出色的療法,市占率也只拿到大約 20%。

  • So we think having both approaches, ZYNLONTA plus rituximab and LOTIS-5 as well as ZYNLONTA plus glofitamab and LOTIS-7 are complementary approaches, which allow us to address different individual patient needs.

    因此我們認為,同時擁有兩種策略——ZYNLONTA 加上利妥昔單抗(rituximab)的 LOTIS-5,以及 ZYNLONTA 加上 glofitamab 的 LOTIS-7——是互補的作法,讓我們能夠滿足不同個別病患的需求。

  • Specifically with LOTIS-5, we believe that having a non-systemic chemo combination can offer a competitive second-line efficacy profile, but also with favorable safety and convenience, especially for patients who either can't access or not suitable for or progress on a CAR-T or bispecific therapy.

    就 LOTIS-5 而言,我們相信採用非全身性化療的組合,能在二線提供具競爭力的療效表現,同時也具備良好的安全性與便利性,特別適用於那些無法取得、或不適合、或在 CAR-T 或雙特異性療法後仍進展的病患。

  • With LOTIS-5, based on the recent data we shared in December, which we believe is very compelling, we think that ZYNLONTA plus glofitamab has the potential to be the preferred bispecific combination in second-line plus DLBCL with a highly competitive efficacy as well as with a manageable safety profile and the potential for off-the-shelf convenient dosing.

    就 LOTIS-5 而言,根據我們在 12 月分享的最新數據(我們認為非常有說服力),我們認為 ZYNLONTA 加上 glofitamab 具備成為二線以上 DLBCL 首選雙特異性組合的潛力,療效高度具競爭力,同時安全性可控,並且有機會提供現成可用(off-the-shelf)且便利的給藥方式。

  • So we believe that both approaches are complementary. Based on our quantitative market research, what we've seen is about 50% of patients are anticipated to get a CAR-T or bispecific. So it still leaves a lot of room for other therapies. And then we, of course, know that many of them, of course, they will progress.

    因此我們相信這兩種策略是互補的。根據我們的量化市場研究,我們看到大約 50% 的病患預期會接受 CAR-T 或雙特異性療法。因此仍然為其他療法留下很大的空間。而且我們當然也知道,其中許多人最終也會出現疾病進展。

  • Michael Schmidt - Analyst

    Michael Schmidt - Analyst

  • Okay. And then, yeah, we saw you have an AACR -- an oral presentation coming up at AACR on your Claudin-6 ADC. And yes, I was just wondering if you can help us understand sort of how important that presentation is in terms of some of the learnings perhaps relative to other ADC platforms like the Daiichi Sankyo technology. How much inside will we gain from that presentation in terms of differentiation?

    好的。另外,是的,我們看到你們在 AACR 會有一場關於 Claudin-6 ADC 的口頭報告。我想請你們協助我們理解,這場報告的重要性,尤其是相較於其他 ADC 平台(例如第一三共的技術)可能帶來的學習。就差異化而言,從那場報告我們能獲得多少洞見?

  • Ameet Mallik - Chief Executive Officer, Director

    Ameet Mallik - Chief Executive Officer, Director

  • Yeah. I think you will see more data that has not been disclosed yet in the public domain, not only on Claudin-6, which, as you mentioned, is an oral presentation, but we also have poster presentations for our PSMA and ASCT2 compounds.

    是的。我想你們會看到更多尚未在公開領域披露的數據,不僅是 Claudin-6(如你所提,是口頭報告),我們也會針對 PSMA 與 ASCT2 的化合物進行海報發表。

  • As you're aware, we're using exatecan with a very novel linker system, which allows us to offset the hydrophobicity of exatecan and tracelessly release it. What we've seen so far preclinically is pretty consistently a therapeutic index that's greater than 10, which is quite differentiated. Relative to DXd, we've seen higher potency, higher (inaudible). We know it's on MDR substrate.

    如你所知,我們使用 exatecan 搭配一套非常新穎的連接子系統,能夠抵消 exatecan 的疏水性,並以無痕(traceless)的方式釋放它。截至目前我們在臨床前看到的結果相當一致:治療指數(therapeutic index)大於 10,這點相當具有差異化。相較於 DXd,我們看到更高的效力、更高的(聽不清楚)。我們知道它是 MDR 的底物。

  • And we've also seen -- we haven't seen ILD, which you see with DXd and other topoisomerase platforms. So we do think the data is differentiating. And as both the oral presentation for Claudin-6 as well as the poster presentations for PSMA and ASCT2, there will be additional, I believe, compelling data that share that hasn't been in public domain at this point.

    此外我們也看到——我們尚未看到 ILD(間質性肺病),但這在 DXd 以及其他拓撲異構酶平台中是會看到的。因此我們確實認為這些數據具有差異化。而在 Claudin-6 的口頭報告以及 PSMA 與 ASCT2 的海報發表中,將會有更多我認為很有說服力的新增數據分享,而這些目前尚未出現在公開領域。

  • Michael Schmidt - Analyst

    Michael Schmidt - Analyst

  • Thank you.

    謝謝。

  • Ameet Mallik - Chief Executive Officer, Director

    Ameet Mallik - Chief Executive Officer, Director

  • Thank you.

    謝謝。

  • Operator

    Operator

  • Gregory Renza, RBC Capital Markets.

    RBC Capital Markets 的 Gregory Renza。

  • Unidentified Participant

    Unidentified Participant

  • Hi guys, thanks so much for the time this morning. It's [Aneesh] on for Greg. Thanks also for the updates and for taking our questions. Just on LOTIS-5, what must the combination of ZYNLONTA and rituximab demonstrate in terms of efficacy and safety to be considered competitive?

    各位好,謝謝今天早上撥冗。我是代 Greg 發言的 [Aneesh]。也謝謝你們的更新並回答我們的問題。關於 LOTIS-5,ZYNLONTA 與利妥昔單抗(rituximab)的組合在療效與安全性方面需要展現到什麼程度,才會被視為具有競爭力?

  • And what are the benchmarks for approval and to make a compelling case for clinical adoption in terms of complete response, median PFS, median DOR and median OS? Thanks so much.

    另外,就核准與臨床採用的說服力而言,在完全緩解率(CR)、中位無惡化存活期(median PFS)、中位緩解持續時間(median DOR)以及中位總存活期(median OS)方面的基準是什麼?非常感謝。

  • Ameet Mallik - Chief Executive Officer, Director

    Ameet Mallik - Chief Executive Officer, Director

  • Yeah, no thanks. For LOTIS-5, the way I think about the competitive set is that the world is going to be sort of CAR-Ts and bispecific-based combinations, of which there's going to be a portion of the population that's going to have access to those therapies and be suitable for those patients.

    好的,謝謝。對 LOTIS-5 而言,我看待競品組合的方式是:市場將會是 CAR-T 與以雙特異性為基礎的各種組合;其中會有一部分族群能取得這些療法,且適合這些病患。

  • But again, we anticipate based on the independent quantitative market research that about half the patients are going to get one of those therapies in the second line setting. And when you look at the other therapies and all the other combinations, whether they do targeted therapies or with chemo-based regimens, they tend to have CR rates anywhere between the 25% to 40% range.

    但同樣地,根據獨立的量化市場研究,我們預期在二線治療情境中,大約一半的病患會接受其中一種療法。而當你看其他療法與各種其他組合,不論是標靶治療或以化療為基礎的方案,它們的 CR 率通常落在 25% 到 40% 之間。

  • So clearly, anything north of 40% would be differentiated. I think what we're encouraged by is when the safety run-in, which was the first 20 patients looking at the combinations of ZYNLONTA plus rituximab prior to the randomized portion of the study, what we saw was that overall response rate of 80% and a complete response rate of 50%.

    因此很明顯,任何高於 40% 的表現都會具有差異化。讓我們感到鼓舞的是,在安全性導入期(safety run-in)——也就是在研究隨機分派部分之前,先觀察 ZYNLONTA 加上利妥昔單抗組合的前 20 位病患——我們看到總反應率(ORR)為 80%,完全緩解率為 50%。

  • So we believe anywhere in that 40% to 50% range is going to be compelling relative to the non-CAR-T and non-bispecific options, which we know is going to be a big opportunity. In terms of PFS, the way this study is powered -- so this is a randomized study versus R-GemOx. What we know is R-GemOx typically has a PFS of anywhere from three to four months.

    因此我們相信,大約 40% 到 50% 的區間,相較於非 CAR-T 與非雙特異性的選項會相當有說服力;而我們知道這會是一個很大的機會。至於 PFS,這項研究的統計設計(power)——這是一項與 R-GemOx 對照的隨機研究。我們知道 R-GemOx 的 PFS 通常大約是 3 到 4 個月。

  • In the STARGLO study, for example, where it was most recently used as a control arm, the PFS was 3.6 months. The way the study is powered is that we need to show approximately a two month difference to have a positive study. So we feel good based on the safety run-in data.

    例如在 STARGLO 研究中,最近一次作為對照組使用時,PFS 是 3.6 個月。本研究的設計是:我們需要顯示大約 2 個月的差異,才能得到陽性結果。因此基於安全性導入期的數據,我們感覺良好。

  • Obviously, it's -- we're blinded to the results of the study. So we have to wait to see the result. But based on the early data, we're quite encouraged by the prospects of having a positive LOTIS-5 study and for it to be clinically relevant, particularly relative to the non-bispecific and non-CAR-T options.

    當然——我們目前對研究結果仍是盲態。所以我們必須等待結果揭盲。但基於早期數據,我們對 LOTIS-5 研究取得陽性結果、且在臨床上具相關性(特別是相較於非雙特異性與非 CAR-T 的選項)抱持相當樂觀的看法。

  • Unidentified Participant

    Unidentified Participant

  • Great, thank you so much. And if I could just squeeze in one more. I guess just on the commercial side, how do you foresee the competitive landscape for third line DLBCL evolving in 2025 and beyond? And how might that differ from '24? Thanks again.

    太好了,非常感謝。如果我可以再擠出一個問題。我想就商業面而言,您如何預期 2025 年及之後第三線 DLBCL 的競爭態勢會如何演變?以及這與 2024 年相比會有何不同?再次感謝。

  • Ameet Mallik - Chief Executive Officer, Director

    Ameet Mallik - Chief Executive Officer, Director

  • Yeah, I think, I mean I think the biggest competitive impact we've seen with the product since the launch is really was the introduction of bispecifics about 18 months ago. Bispecifics now have taken about a third of the third line plus market.

    是的,我想——我的意思是,我認為自產品上市以來我們看到的最大競爭影響,確實是大約 18 個月前雙特異性抗體的引入。目前雙特異性抗體已經拿下第三線及以上市場大約三分之一的份額。

  • I think what I'm happy about is that during the period, and if you look at the past several quarters, we've been in that $16 million to $18 million sales per quarter range. We had some fluctuation due to ordering pattern variability, but we've been in that $16 million to $18 million range pretty consistently over the past several quarters despite this bispecific combination.

    我感到欣慰的是,在那段期間,如果你看過去幾個季度,我們每季銷售額一直維持在 1,600 萬到 1,800 萬美元的區間。我們因訂購模式的變動而有些波動,但在過去幾個季度,即使有這些雙特異性方案的競爭,我們仍相當一致地維持在 1,600 萬到 1,800 萬美元的範圍。

  • The only real new competitive impact in the third line plus setting is the question before that Eric asked about the ADCETRIS plus R-squared. So we believe, of course, there's going to be some impact, but we believe it will be relatively limited, particularly as there's likely to be more community use and really in place of some of the other regimens like R-squared and R-based chemo.

    在第三線及以上的治療情境中,唯一真正新的競爭影響,就是先前 Eric 問到的 ADCETRIS 加 R-squared 的問題。因此我們當然相信會有一些影響,但我們認為影響會相對有限,特別是因為它可能更多在社區端使用,而且主要是取代其他一些療法方案,例如 R-squared 以及以 R 為基礎的化療。

  • Unidentified Participant

    Unidentified Participant

  • Thank you.

    謝謝。

  • Operator

    Operator

  • Sudan Loganathan, Stephens.

    Sudan Loganathan,Stephens。

  • Sudan Loganathan - Analyst

    Sudan Loganathan - Analyst

  • Thank you, for the update and for taking my questions. My first one is, can you provide some examples of comparable bispecifics that demonstrated meaningful market share gain with the DLBCL patients through compendia listing? And then what were the number of patients in those bispecific clinical trials that were run that got published and were considered for compendia listing?

    謝謝你們的更新,也謝謝回答我的問題。第一個問題是,你們能否提供一些可比的雙特異性抗體案例,這些產品透過收錄於彙編(compendia)清單,在 DLBCL 病患中取得了有意義的市占提升?另外,那些雙特異性臨床試驗中、已發表並被納入彙編清單考量的病患人數是多少?

  • Ameet Mallik - Chief Executive Officer, Director

    Ameet Mallik - Chief Executive Officer, Director

  • Yes. So recently, I think it's too soon to tell what the uptake could be. But I think what we know is that very recently, glofitamab plus GemOx, epcoritamab plus GemOx and mosun plus polatuzumab have all been very recently added to NCCN guidelines in the preferred regimen based on roughly 100 patients.

    可以。所以就近期而言,我認為現在判斷其採用速度還太早。但我們知道的是,最近,glofitamab 加 GemOx、epcoritamab 加 GemOx,以及 mosun 加 polatuzumab,都非常近期被加入 NCCN 指南的優選方案(preferred regimen),其依據大約是 100 名病患的資料。

  • So when we look at all those analogs, we think about 100 patients is what's required to get into guidelines. That's what -- approximately what all three of those regimens have. And too soon to tell what the uptake is going to be.

    因此當我們看這些類比案例時,我們認為大約 100 名病患就是進入指南所需的規模。這——大致上就是這三個方案各自所具備的病患數量。而目前仍太早判斷其採用率會是多少。

  • Obviously, as you know, with any compendia listing, we, of course, will not promote off-label. And I assume none of these companies are going to promote off-label. But these become available to physicians to do what's best for the patients. And once you get into preferred regimen, payers, of course, will reimburse based on preferred listings typically.

    顯然,如你所知,任何彙編收錄情況下,我們當然不會推廣適應症外使用(off-label)。我也假設這些公司都不會推廣適應症外使用。但這些選項會提供給醫師,讓他們為病患做出最好的決定。而一旦進入優選方案,付款方通常也會依據優選收錄來進行給付。

  • Sudan Loganathan - Analyst

    Sudan Loganathan - Analyst

  • Got it. Thank you. And if I can squeeze in one more. I just wanted to ask on how long do you anticipate it will take to kind of achieve that peak penetration predictions for ZYNLONTA after achieving compendia listing or even a potential approval in the second and third line setting.

    了解。謝謝。如果我可以再問一個。我想請教的是,在 ZYNLONTA 取得彙編收錄,或甚至在第二線與第三線治療情境中可能獲得核准之後,你們預期需要多久才能達到你們所預測的峰值滲透率?

  • I know like whenever it was first approved, it was pretty swift in gaining market share. So just kind of curious if you expect the same type of ramp once it's added to listing?

    我知道它剛獲核准時,市占提升相當迅速。所以我只是好奇,一旦被加入收錄清單後,你們是否也預期會有同樣類型的爬坡速度?

  • Ameet Mallik - Chief Executive Officer, Director

    Ameet Mallik - Chief Executive Officer, Director

  • Yeah. We haven't guided to what the peak penetration would be the time frame. But what I can tell you is if you look at the other analogs that have been introduced up to this point, typically, the peak penetration is achieved usually within the first two years.

    是的。我們尚未對峰值滲透率或時間框架提供指引。但我可以告訴你的是,如果你看截至目前已推出的其他類比產品,通常峰值滲透率多半會在前兩年內達成。

  • Oncologists and hematologists, I think, are always searching to use the best products for the patients, especially unfortunately, in something that's life-threatening and where patients, especially when they relapse post the front line, they tend to -- the prognosis is not great, unfortunately, for these patients. And so usually, what you do see is adoption pretty quickly.

    我認為腫瘤科與血液科醫師總是在尋找對病患最好的產品,尤其不幸的是,這是一種危及生命的疾病;而且病患一旦在一線治療後復發,通常——這些病患的預後不佳,令人遺憾。因此你通常會看到採用速度相當快。

  • For example, polatuzumab in the front line, obviously, which showed good data in the frontline setting seems to have plateaued, and it's in about two years. We see bispecific growth going down a little bit in the third line setting, we're at that 18 month mark. So that's typically what we've seen.

    例如,前線治療中的 polatuzumab,顯然在前線治療情境中顯示了良好數據,似乎已趨於平台期,大約是在兩年左右。我們看到第三線治療情境中的雙特異性抗體成長略有放緩,目前大約在 18 個月的時間點。所以這通常就是我們所看到的情況。

  • I don't want to again predict what's going to happen for our products, but I'd just say that's typically what's happened up to this point in the DLBCL setting.

    我不想再次去預測我們產品會發生什麼,但我只能說,到目前為止在 DLBCL 治療領域通常就是這樣的發展。

  • Sudan Loganathan - Analyst

    Sudan Loganathan - Analyst

  • Thanks. I appreciate it.

    謝謝。我很感激。

  • Operator

    Operator

  • There are no further questions at this time. That concludes our question-and-answer session. I'd like to turn the conference back to our CEO, Ameet Mallik for closing remarks. Ameet?

    目前沒有其他問題。問答環節到此結束。我想把會議交回給我們的執行長 Ameet Mallik 作結語。Ameet?

  • Ameet Mallik - Chief Executive Officer, Director

    Ameet Mallik - Chief Executive Officer, Director

  • Well, I want to thank you all for joining our call today and for your continued support. We look forward to keeping you updated on our progress. Operator, please end the call.

    好的,我想感謝各位今天參加我們的電話會議,並感謝你們持續的支持。我們期待持續向各位更新我們的進展。接線員,請結束通話。

  • Operator

    Operator

  • Ladies and gentlemen, this concludes today's conference call. Thank you for your participation. You may now disconnect.

    各位女士、先生,今天的電話會議到此結束。感謝各位的參與。您現在可以掛線。